Lexaria Bioscience (LXX) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Lexaria receives HREC approval for DehydraTECH-tirzepatide GLP-1 study armFebruary 24, 2025 | markets.businessinsider.comLexaria to investigate commercial opportunities for DehydraTECH-LiraglutideFebruary 21, 2025 | markets.businessinsider.comInsider Buying: Richard Christopher Acquires 50,000 Shares of Lexaria Bioscience Corp (LEXX)December 3, 2024 | gurufocus.comLexaria Bioscience signs contract for DehydraTECH GLP-1 biodistribution studyNovember 14, 2024 | markets.businessinsider.comLexaria Bioscience Launches Innovative Drug StudyNovember 14, 2024 | markets.businessinsider.comLexaria Bioscience appoints new CFO Michael ShankmanOctober 4, 2024 | investing.comTinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 DrugsSeptember 20, 2024 | msn.comCannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery ...August 27, 2024 | msn.comCBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes ControlAugust 21, 2024 | msn.comCannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization StudyAugust 19, 2024 | msn.comLEXX: GLP-1 Agonist Program UpdatesJuly 23, 2024 | msn.comLEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024April 9, 2024 | msn.comLexaria Bioscience Stock (NASDAQ:LEXXW) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comLexaria submits IND to begin Phase 1b study of DehyraTECH-CBDJanuary 30, 2024 | msn.comBuy Rating on Lexaria Bioscience: Promising DehydraTECH Study and Market PotentialDecember 1, 2023 | markets.businessinsider.comLexaria stock rallies 20% on positive GLP-1 drug delivery studyNovember 27, 2023 | msn.comMaxim Group Initiates Coverage of Lexaria Bioscience (LEXX) with Buy RecommendationJuly 22, 2023 | msn.comLexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal StudyJune 16, 2023 | benzinga.comCannabisNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual MeetingMay 12, 2023 | marketwatch.comLexaria Bioscience shares are trading lower after the company priced a 2.1 million unit offering at $0.95 per unit.May 9, 2023 | benzinga.comLexaria Bioscience prices $2.0M stock offeringMay 9, 2023 | msn.comLexaria's Human Clinical Nicotine Study Completes Dosing as PlannedMay 8, 2023 | benzinga.comLEXX: DehydraTECH CBD May Offer New Mechanism of ActionApril 26, 2023 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol LevelsMarch 4, 2023 | finanznachrichten.deLexaria Bioscience Corp. Common Stock (LEXX)February 22, 2023 | nasdaq.comLexaria Bioscience Corp. (LEXX)September 26, 2022 | finance.yahoo.comLexaria Receives New Patent in MexicoAugust 31, 2022 | finance.yahoo.comNetworkNewsAudio - Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension TreatmentsAugust 12, 2022 | marketwatch.comCannabisNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND ProgramAugust 12, 2022 | marketwatch.comLexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment SolutionAugust 11, 2022 | apnews.comLexaria Discusses Valuation Metrics for Biotech IndustryAugust 11, 2022 | finance.yahoo.comLexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for HypertensionAugust 10, 2022 | finance.yahoo.comLexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse EventsJuly 27, 2022 | msn.comLexaria Signs Manufacturing and License Agreements with BevNologyJune 21, 2022 | finance.yahoo.comLexaria stock soars 19% on 2 manufacturing/license agreements with BevNologyJune 21, 2022 | seekingalpha.comLexaria inks licensing deal for drug delivery tech with Premier Wellness for Japanese marketJune 3, 2022 | seekingalpha.comLexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech SpaceMay 26, 2022 | finance.yahoo.comLexaria Bioscience Corp. LEXXWJanuary 4, 2022 | stockhouse.comRead Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?December 8, 2021 | benzinga.comBhang announces expanded partnership with US-based Trulieve CannabisOctober 2, 2021 | proactiveinvestors.comBhang brings on Wes Eder as global vice president of revenueSeptember 16, 2021 | proactiveinvestors.comLexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension PatientsSeptember 7, 2021 | benzinga.com Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXX and its competitors with MarketBeat's FREE daily newsletter. Email Address LXX Media Mentions By Week LXX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXX News Sentiment▼0.000.23▲Average Consumer Defensive News Sentiment LXX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXX Articles This Week▼00▲LXX Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SAP News PBH News MFI News JWEL News SOY News HLF News SWP News BU News VPI News L News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CNSX:LXX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
